Recordati Industria Chimica e Farmaceutica S.p.A. provided revenue guidance for the year 2024 and 2025. For 2024, the company expects revenue between EUR 2.260 billion and EUR 2.320 billion, reflecting mid-single-digit growth of SPC at constant exchange rate and double-digit growth of rare disease at constant exchange rate and both of them organically.

For 2025, the company expects revenue above EUR 2.4 billion from the current portfolio.